-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*Only for medical professionals to read for reference.
On March 13, the Lung Cancer Innovation Forum was successfully held.
Many experts discussed the progress of lung cancer targeting and immunotherapy.
On March 13, 2021, the lung cancer innovation forum with the theme of "writing a legend" kicked off.
This forum was hosted by Roche Pharmaceuticals and was held simultaneously in multiple places through online live broadcast.
Experts and scholars in the field of lung cancer at home and abroad gathered together to exchange in-depth exchanges on topics such as lung cancer targeting, frontier progress in immunotherapy, and the application of advanced technologies in lung cancer diagnosis and treatment.
At the beginning of the conference, the presidium of the conference delivered speeches and wished the conference a smooth convening.
Subsequently, Zhou Hong, President of Roche Pharmaceuticals China, said in his opening speech: “Roche adheres to the concept of'being the needs of patients first' and has long-term roots in the field of lung cancer.
It has anti-angiogenesis, EGFR-TKI, ALK-positive targeted therapies, and immunity.
A variety of innovative drugs for tumor treatment.
With the strong support of experts, it benefited more than 70,000 lung cancer patients in the last year alone.
In the
future, Roche will uphold its long-term commitment to Chinese patients and bring them to Chinese patients through research and development innovation.
More innovative drugs.
At the same time, we will continue to vigorously support the generation of localized data to meet domestic clinical needs, and explore new models of individualized medical care.
We hope that with our joint efforts, we will build a patient-centric ecosystem and help a healthy China!" The main venue of the Lung Cancer Innovation Forum is divided into two chapters: targeted therapy and immunotherapy, bringing together well-known domestic experts to share the hotspots and latest developments in this field.
Targeted therapy for lung cancer: development in depth and breadth.
The first speaker is Professor Tony MOK of the Chinese University of Hong Kong.
His lecture is "Highlights of Targeted Therapy: Past and Future", which is especially targeted for lung cancer treatment.
A systematic review and future prospects were made to the development of treatment.Professor Tony MOK pointed out that in recent years, the death rate of lung cancer has fallen sharply, mainly due to the emergence of targeted therapies, and the emergence of each new generation of new drugs is also continuously improving the treatment outcome of patients with positive driver genes.
With the continuous development of treatment methods and detection technologies, it is still necessary to continue to pay attention to disease biology, biomarkers and clinical research quality.
It is believed that more and more new therapeutic targets and drug resistance mechanisms will be discovered and elucidated in the future, and Gradually change clinical practice.
Professor Lu Shun from the Chest Hospital of Shanghai Jiaotong University brought a professional sharing titled "Turning Evidence into Practice: Rare Mutation Targets in Lung Cancer".
Professor Lu Shun pointed out that non-small cell lung cancer (NSCLC) is not a single disease.
It has multiple molecular types.
In addition to the relatively high incidence of KRAS, EGFR, and ALK targets, it also has multiple types of low incidence.
Rare mutation target.
In the past 5 years, several milestone studies have been published in the field of rare target lung cancer, and many countries around the world have successively approved several rare target inhibitors.
However, there are still many unmet clinical needs, including the basic information and prognosis of rare diseases, the timing of detection of rare targets, whether liquid biopsy guidance is feasible, how to optimize the choice and use of drugs, how to deal with drug resistance, and the treatment of co-mutation Strategies, etc.
, require further research and exploration.
Subsequently, Ms.
Li Wei, vice president of Roche Pharmaceuticals Medicine and Personalized Medicine Department, introduced Roche's lung cancer research and development pipeline and personalized medicine related content.
Ms.
Li Wei said that increasing the immune system's killing of tumor cells is still the core of Roche's anti-tumor product development.
In terms of immunotherapy drugs in the field of lung cancer, some of Roche’s research pipelines include: (1) fully humanized anti-TIGIT IgG1 monoclonal antibody Tiragolumab, currently in the phase II/III phase of research; (2) immune cytokine fusion protein Simlukafusp alfa, currently In the phase Ia/Ib research phase; (3) PD-1/TIM3 bispecific antibody, by combining with two immune checkpoint inhibitor receptors PD-1/TIM-3, revitalizes the vitality of inactivated T cells The killing of tumors is currently in phase I clinical research.
The roundtable dialogue session was hosted by Professor Wu Yilong from Guangdong Provincial People’s Hospital, Professor Lu Shun from Shanghai Jiaotong University Thoracic Hospital, Professor Zhang Li from Sun Yat-sen University Cancer Center, Professor Fan Yun from Cancer Hospital Affiliated to the Chinese Academy of Sciences, Professor Tony MOK from the Chinese University of Hong Kong, Ms.
Li Wei, vice president of the Chinese Medicine and Personalized Medicine Department of Roche Pharmaceuticals, had a lively discussion on targeted therapy of lung cancer.
Lung cancer immunotherapy: evidence-based and exploring peers Professor Zhou Caicun from Shanghai Pulmonary Hospital Affiliated to Tongji University brought a professional sharing titled "Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Facts and Hopes", from immunization single drugs and immune combined chemotherapy , Immunization combined with anti-vascular, new exploration of immunity (TIGIT, LAG-3, etc.
) comprehensively introduces the application of immunotherapy in NSCLC in multiple dimensions.
Professor Zhou Caicun pointed out that NSCLC has entered a new era of immunotherapy, and immune monotherapy has become the standard first-line treatment for patients with advanced NSCLC with high PD-L1 expression.
Combined immune chemotherapy and combined immune anti-vascular + chemotherapy are also new first-line treatments for patients with metastatic NSCLC.
standard.
Although immunotherapy has changed the treatment pattern of NSCLC, not all patients can benefit from tumor immunotherapy.
In the future, it is necessary to further understand tumor microenvironment and immune resistance mechanisms, find immune targets of different signaling pathways, and develop corresponding immunity Drugs; explore the best combination therapy model, find more suitable biomarkers, and bring more effective options for patients with advanced NSCLC.
Professor Chen Haiquan from the Cancer Hospital of Fudan University pointed out in a sharing titled "Break the Limits of Non-Small Cell Lung Cancer Research" that if early lung cancer is detected in time, there may be a chance of being cured after surgery.
The results of the early screening of lung cancer in the Chinese population once again remind us that there are different risk factors for lung cancer in the East and the West.
The lung cancer risk prediction model based on the Western population may not be directly applicable to the Asian population.
Chinese researchers have made continuous exploration in this regard.
the study.
After entering the age of immunotherapy, NSCLC neoadjuvant/adjuvant therapy has new exploration directions: including immune single-drug neoadjuvant/adjuvant therapy and immune combined chemotherapy neoadjuvant therapy, etc.
, which have good effects in neoadjuvant/adjuvant therapy. The search for more predictive biomarkers, the choice of single-drug or combination drug regimens, immune neoadjuvant therapy, and the timing of surgery are awaiting the joint efforts of researchers around the world to further explore.
Afterwards, Professor Stephen Liu from Georgetown University in Washington shared on the development of immunotherapy for small cell lung cancer.
Professor Stephen Liu pointed out that the IMpower 133 study showed that the median overall survival (OS) of patients with extensive-stage small cell lung cancer (ES-SCLC) was significantly prolonged in the first-line treatment of atilizumab plus chemotherapy, and more than half of the patients survived more than 1 year.
Immunotherapy has a good performance in ES-SCLC, but there is still a long way to explore SCLC treatment in the future, and a deeper understanding of the disease characteristics of SCLC is needed to improve the efficacy of SCLC treatment.
With the continuous development of clinical research, the goal of SCLC precision treatment has gradually become clear.
The roundtable dialogue session was hosted by Professor Zhou Caicun from Shanghai Pulmonary Hospital Affiliated to Tongji University, Professor Chen Haiquan from Fudan University Tumor Hospital, Professor Han Baohui from the Chest Hospital of Shanghai Jiaotong University, Professor Wang Baocheng from the 960th Hospital of the People’s Liberation Army, and Shanghai Chest Hospital, Shanghai Jiaotong University Professor Fu Xiaolong, Professor Stephen Liu from Georgetown University in Washington, USA, and Ms.
Li Wei, Vice President of Roche Pharmaceutical Medicine and Personalized Medicine, further discussed the development of lung cancer immunotherapy.
At the end of the meeting, Professor Zhou Caicun concluded that there are continuous innovations in lung cancer targeted therapy.
Immunotherapy has become a hot spot in today’s research.
There are still many important problems to be resolved.
There is a long way to go to strengthen precision treatment of lung cancer.
I hope there will be more in the future.
The innovative drugs are applied to the clinic.
This innovation forum provides experts and scholars in the field of lung cancer with a high-end platform for learning and communication, and in-depth exchanges and discussions on two hot spots in the field of lung cancer-targeted therapy and immunotherapy.
The successful convening of the forum provided a direction for the optimization and development of lung cancer treatment, and contributed to the exploration of a better path for lung cancer treatment in China.
Looking forward to the next Lung Cancer Innovation Forum can bring us more exciting content.
On March 13, the Lung Cancer Innovation Forum was successfully held.
Many experts discussed the progress of lung cancer targeting and immunotherapy.
On March 13, 2021, the lung cancer innovation forum with the theme of "writing a legend" kicked off.
This forum was hosted by Roche Pharmaceuticals and was held simultaneously in multiple places through online live broadcast.
Experts and scholars in the field of lung cancer at home and abroad gathered together to exchange in-depth exchanges on topics such as lung cancer targeting, frontier progress in immunotherapy, and the application of advanced technologies in lung cancer diagnosis and treatment.
At the beginning of the conference, the presidium of the conference delivered speeches and wished the conference a smooth convening.
Subsequently, Zhou Hong, President of Roche Pharmaceuticals China, said in his opening speech: “Roche adheres to the concept of'being the needs of patients first' and has long-term roots in the field of lung cancer.
It has anti-angiogenesis, EGFR-TKI, ALK-positive targeted therapies, and immunity.
A variety of innovative drugs for tumor treatment.
With the strong support of experts, it benefited more than 70,000 lung cancer patients in the last year alone.
In the
future, Roche will uphold its long-term commitment to Chinese patients and bring them to Chinese patients through research and development innovation.
More innovative drugs.
At the same time, we will continue to vigorously support the generation of localized data to meet domestic clinical needs, and explore new models of individualized medical care.
We hope that with our joint efforts, we will build a patient-centric ecosystem and help a healthy China!" The main venue of the Lung Cancer Innovation Forum is divided into two chapters: targeted therapy and immunotherapy, bringing together well-known domestic experts to share the hotspots and latest developments in this field.
Targeted therapy for lung cancer: development in depth and breadth.
The first speaker is Professor Tony MOK of the Chinese University of Hong Kong.
His lecture is "Highlights of Targeted Therapy: Past and Future", which is especially targeted for lung cancer treatment.
A systematic review and future prospects were made to the development of treatment.Professor Tony MOK pointed out that in recent years, the death rate of lung cancer has fallen sharply, mainly due to the emergence of targeted therapies, and the emergence of each new generation of new drugs is also continuously improving the treatment outcome of patients with positive driver genes.
With the continuous development of treatment methods and detection technologies, it is still necessary to continue to pay attention to disease biology, biomarkers and clinical research quality.
It is believed that more and more new therapeutic targets and drug resistance mechanisms will be discovered and elucidated in the future, and Gradually change clinical practice.
Professor Lu Shun from the Chest Hospital of Shanghai Jiaotong University brought a professional sharing titled "Turning Evidence into Practice: Rare Mutation Targets in Lung Cancer".
Professor Lu Shun pointed out that non-small cell lung cancer (NSCLC) is not a single disease.
It has multiple molecular types.
In addition to the relatively high incidence of KRAS, EGFR, and ALK targets, it also has multiple types of low incidence.
Rare mutation target.
In the past 5 years, several milestone studies have been published in the field of rare target lung cancer, and many countries around the world have successively approved several rare target inhibitors.
However, there are still many unmet clinical needs, including the basic information and prognosis of rare diseases, the timing of detection of rare targets, whether liquid biopsy guidance is feasible, how to optimize the choice and use of drugs, how to deal with drug resistance, and the treatment of co-mutation Strategies, etc.
, require further research and exploration.
Subsequently, Ms.
Li Wei, vice president of Roche Pharmaceuticals Medicine and Personalized Medicine Department, introduced Roche's lung cancer research and development pipeline and personalized medicine related content.
Ms.
Li Wei said that increasing the immune system's killing of tumor cells is still the core of Roche's anti-tumor product development.
In terms of immunotherapy drugs in the field of lung cancer, some of Roche’s research pipelines include: (1) fully humanized anti-TIGIT IgG1 monoclonal antibody Tiragolumab, currently in the phase II/III phase of research; (2) immune cytokine fusion protein Simlukafusp alfa, currently In the phase Ia/Ib research phase; (3) PD-1/TIM3 bispecific antibody, by combining with two immune checkpoint inhibitor receptors PD-1/TIM-3, revitalizes the vitality of inactivated T cells The killing of tumors is currently in phase I clinical research.
The roundtable dialogue session was hosted by Professor Wu Yilong from Guangdong Provincial People’s Hospital, Professor Lu Shun from Shanghai Jiaotong University Thoracic Hospital, Professor Zhang Li from Sun Yat-sen University Cancer Center, Professor Fan Yun from Cancer Hospital Affiliated to the Chinese Academy of Sciences, Professor Tony MOK from the Chinese University of Hong Kong, Ms.
Li Wei, vice president of the Chinese Medicine and Personalized Medicine Department of Roche Pharmaceuticals, had a lively discussion on targeted therapy of lung cancer.
Lung cancer immunotherapy: evidence-based and exploring peers Professor Zhou Caicun from Shanghai Pulmonary Hospital Affiliated to Tongji University brought a professional sharing titled "Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Facts and Hopes", from immunization single drugs and immune combined chemotherapy , Immunization combined with anti-vascular, new exploration of immunity (TIGIT, LAG-3, etc.
) comprehensively introduces the application of immunotherapy in NSCLC in multiple dimensions.
Professor Zhou Caicun pointed out that NSCLC has entered a new era of immunotherapy, and immune monotherapy has become the standard first-line treatment for patients with advanced NSCLC with high PD-L1 expression.
Combined immune chemotherapy and combined immune anti-vascular + chemotherapy are also new first-line treatments for patients with metastatic NSCLC.
standard.
Although immunotherapy has changed the treatment pattern of NSCLC, not all patients can benefit from tumor immunotherapy.
In the future, it is necessary to further understand tumor microenvironment and immune resistance mechanisms, find immune targets of different signaling pathways, and develop corresponding immunity Drugs; explore the best combination therapy model, find more suitable biomarkers, and bring more effective options for patients with advanced NSCLC.
Professor Chen Haiquan from the Cancer Hospital of Fudan University pointed out in a sharing titled "Break the Limits of Non-Small Cell Lung Cancer Research" that if early lung cancer is detected in time, there may be a chance of being cured after surgery.
The results of the early screening of lung cancer in the Chinese population once again remind us that there are different risk factors for lung cancer in the East and the West.
The lung cancer risk prediction model based on the Western population may not be directly applicable to the Asian population.
Chinese researchers have made continuous exploration in this regard.
the study.
After entering the age of immunotherapy, NSCLC neoadjuvant/adjuvant therapy has new exploration directions: including immune single-drug neoadjuvant/adjuvant therapy and immune combined chemotherapy neoadjuvant therapy, etc.
, which have good effects in neoadjuvant/adjuvant therapy. The search for more predictive biomarkers, the choice of single-drug or combination drug regimens, immune neoadjuvant therapy, and the timing of surgery are awaiting the joint efforts of researchers around the world to further explore.
Afterwards, Professor Stephen Liu from Georgetown University in Washington shared on the development of immunotherapy for small cell lung cancer.
Professor Stephen Liu pointed out that the IMpower 133 study showed that the median overall survival (OS) of patients with extensive-stage small cell lung cancer (ES-SCLC) was significantly prolonged in the first-line treatment of atilizumab plus chemotherapy, and more than half of the patients survived more than 1 year.
Immunotherapy has a good performance in ES-SCLC, but there is still a long way to explore SCLC treatment in the future, and a deeper understanding of the disease characteristics of SCLC is needed to improve the efficacy of SCLC treatment.
With the continuous development of clinical research, the goal of SCLC precision treatment has gradually become clear.
The roundtable dialogue session was hosted by Professor Zhou Caicun from Shanghai Pulmonary Hospital Affiliated to Tongji University, Professor Chen Haiquan from Fudan University Tumor Hospital, Professor Han Baohui from the Chest Hospital of Shanghai Jiaotong University, Professor Wang Baocheng from the 960th Hospital of the People’s Liberation Army, and Shanghai Chest Hospital, Shanghai Jiaotong University Professor Fu Xiaolong, Professor Stephen Liu from Georgetown University in Washington, USA, and Ms.
Li Wei, Vice President of Roche Pharmaceutical Medicine and Personalized Medicine, further discussed the development of lung cancer immunotherapy.
At the end of the meeting, Professor Zhou Caicun concluded that there are continuous innovations in lung cancer targeted therapy.
Immunotherapy has become a hot spot in today’s research.
There are still many important problems to be resolved.
There is a long way to go to strengthen precision treatment of lung cancer.
I hope there will be more in the future.
The innovative drugs are applied to the clinic.
This innovation forum provides experts and scholars in the field of lung cancer with a high-end platform for learning and communication, and in-depth exchanges and discussions on two hot spots in the field of lung cancer-targeted therapy and immunotherapy.
The successful convening of the forum provided a direction for the optimization and development of lung cancer treatment, and contributed to the exploration of a better path for lung cancer treatment in China.
Looking forward to the next Lung Cancer Innovation Forum can bring us more exciting content.
